Abstract: Up to 20% of depressed patients demonstrate treatment resistance to one or more adequate antidepressant trials, resulting in a disproportionately high burden of illness. Ketamine is a non-barbiturate, rapid-acting general anesthetic that has been increasingly studied in treatment resistant depression (TRD), typically at sub-anesthetic doses (0.5 mg/kg over 40 min by intravenous infusion). More recent data suggest that ketamine may improve response rates to electroconvulsive therapy (ECT) when used as an adjunct, but also as a sole agent. In the ECT setting, a dose of 0.8 mg/kg or greater of ketamine demonstrates improved reduction in depressive symptoms than lower doses; however, inconsistency and significant heterogeneity among studies exists. Clinical predictors of responses to ketamine have been suggested in terms of non-ECT settings. Ketamine does increase seizure duration in ECT, which is attenuated when concomitant barbiturate anesthetics are used. However, most studies are small, with considerable heterogeneity of the sample population and variance in dosing strategies of ketamine, ECT, and concomitant medications, and lack a placebo control, which limits interpretation. Psychotomimetic and cardiovascular adverse effects are reported with ketamine. Cardiovascular adverse effects are particularly relevant when ketamine is used in an ECT setting. Adverse effects may be mitigated with concurrent propofol; however, this adds complexity and cost compared to standard anesthesia. Long-term adverse effects are still unknown, but relevant, given recent class concerns for anesthetic and sedative agents.
Introduction
Major depressive disorder (MDD) is defined as "treatment-resistant" depression (TRD) if a patient does not respond to one or more adequate antidepressant trials. TRD occurs at rates of 12%-20% among all depressed patients, and is associated with a disproportionately high burden of illness compared with patients who respond to treatment. 1 Ketamine is a non-barbiturate, rapid-acting general anesthetic with an onset of action within 30 s when given by intravenous (iv) injection at an anesthetic dose of 2 mg/kg (range=1-4.5 mg/kg). 2 Most randomized controlled trials (RCTs) report on ketamine's safety and efficacy in TRD, in a non-electroconvulsive therapy (ECT) setting, when administered by iv infusion at a dose of 0.5 mg/kg over 40 min. 3 A growing body of literature suggests that sub-anesthetic doses of ketamine may reduce the time between initiation of therapy and time to response and/or remission, in TRD, with or without concomitant ECT. 4 Ketamine may also improve the response rates to ECT when used concurrently as an adjunct.
Methodology
The following databases were searched: Pubmed, Embase, PsycINFO (1987 to present), and MEDLINE (1946 to present). The following search terms were used: ketamine, N-methyl d-aspartate, NMDA antagonist, ECT, electroconvulsive therapy, electroshock therapy, major depressive disorder, major depression, MDD, treatment-resistant depressive disorder. Studies were included if they met the following criteria: language, English; publication status, published trials; design, RCT; intervention, ketamine administration alone without ECT for treatment of MDD, ketamine administration with other agents without ECT for treatment of MDD, ketamine administration as an anesthetic for ECT for treatment of MDD, ketamine administration as an anesthetic for ECT along with other agents for treatment of MDD; participants, diagnosis of MDD, TRD, psychotic TRD, bipolar depression.
Studies were excluded if they met the following criteria: (1) Studies of ketamine use in a non-ECT setting using 0.5 mg/kg iv infusion over 40 min, unless investigating clinical predictors for response or use in combination with other specified agents for treatment of TRD; (2) cross-over studies -due to the potential of carry-over effects; (3) studies that did not investigate ketamine as a treatment of depression; and (4) studies that did not report the efficacy of ketamine as one of the primary objectives.
The level of evidence for each study was assessed using prespecified criteria 6 ( Table 1 ). The search generated 704 results, of which 26 studies met the inclusion criteria. Ten additional resources were used for background information purposes. Two additional studies were included from the bibliographies of relevant studies.
Intravenous ketamine in an ECT setting
A number of studies have investigated the use of ketamine, either alone or in addition to other anesthetic agents, and at various doses for induction of anesthesia in ECT (Table 2) . [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] When compared to control anesthesia, ketamine alone, or as an adjunctive agent to other anesthetics, significantly reduced depression severity in a number of studies. 7, 8, 10, 14, 18 Some studies have also shown an increased seizure duration if ketamine was used as a sole anesthetic, or in combination with other anesthetics, when compared to ketamine-free anesthesia. 9, 10, 21 Significant cognitive improvement was also seen with ketamine, especially in patients with higher cognitive impairment at baseline. 10 Several studies showed a more rapid response to ECT in patients receiving ketamine, despite the overall end effect being non-significant. 10, 13 When considering dose-related efficacy, a majority of studies demonstrated efficacy with ketamine doses equal to or greater than 0.8 mg/kg, which may provide a signal for interpretation. One study, however, did not find a significant improvement in depressive symptoms when a dose of 2 mg/kg was used. Given the significant heterogeneity of studies, as well as a lack of high quality studies, conclusive results around doserelated efficacy were not possible. At best, this could be considered as a guide for future research.
In contrast, a few RCTs have not found ketamine to be superior to other anesthetics in depressive symptom reduction 
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Ketamine's role in eCT and non-eCT settings RCT: (1) propofol 1.5 mg/kg iv; (2) ketamine 0.8 mg/kg iv; or (3) propofol 1.5 mg/kg iv plus ketamine 0.8 mg/kg iv.
HDRS scores 1 day before eCT and days 1, 2, 3, and 7 after eCT. HDRS scores improved earlier with ketamine and propofol+ketamine, compared with propofol.
Fewer adverse events with propofol+ketamine than with ketamine. No differences in change in symptom severity. HDRS-17, BPRS at baseline, after 1st, 2nd, 3rd, 4th, 6th, and 8th treatments. K and KP groups showed statistically significant higher response rates after the 3rd eCT (HDRS-17= (1) MADRS prior to eCT, after 6 eCT treatments, 1-3 days after the end of the eCT course, and 1 month later. No significant difference was found in MADRS scores between the groups over the whole course. A significant time-by-group interaction was found over the first week of treatment (F(1, 40)=4.555, P=0.039,
indicating improvement in the ketamine group.
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Jankauskas et al or improved cognition, [15] [16] [17] 19, 20 even if the seizure duration was prolonged with ketamine. 11 The effect of ketamine on seizure duration varied between studies, with some demonstrating no difference between ketamine and controls. 20 Of note, most of the studies employed different methods of ECT administration, such as dose titration, 11 which could explain some of the observed differences in treatment efficacy.
Intravenous ketamine in a non-ECT setting
When used as a general anesthetic together with propofol and fentanyl for orthopedic surgery in patients with MDD, ketamine (1 mg/kg) demonstrated significant reductions in depressed mood, suicidal tendencies, somatic anxiety, and hypochondriasis (Table 3) . [22] [23] [24] Lenze et al 23 attempted to demonstrate the efficacy and safety of prolonged ketamine infusion (0.6 mg/kg/h over 96 h) vs a single dose (0.5 mg/kg for 40 min), both with coadministration of clonidine (0.3 mg twice daily) in patients with TRD. Although there was no difference in MontgomeryAsberg Depression Rating Scale (MADRS) scores between prolonged infusion and a single dose of ketamine, a more sustained antidepressant response (spearman correlation coefficient between S-ketamine concentration and MADRS change from baseline: 0.75 for 96-hour arm and 0.17 for 40-minute arm; p,0.05) was observed at 8 weeks following prolonged infusion. Li et al 24 compared single bolus ketamine at doses of 0.5 mg/kg and 0.2 mg/kg, and a single bolus of normal saline in patients with TRD. The investigators found no significant difference between the two ketamine treatment strategies, but both treatments were significantly more effective than placebo (PBO) (Hamilton Depression Rating Scale [HDRS] reduction of 37.8%, 38.2%, and 26.7%, respectively).
Ketamine with adjunctive agents in non-ECT setting
Three studies investigated adjunctive use of riluzole in patients receiving ketamine infusion (Table 4) . [25] [26] [27] Riluzole is a glutamatergic modulator postulated to induce a rapid response to ketamine, and to maintain remission without the potential psychotomimetic side effects associated with ketamine. 25 When dosed at 50 mg twice daily for 4 weeks following a single ketamine infusion (0.5 mg/kg) in patients with TRD, riluzole did not appear to significantly prolong the duration of response (time to relapse=17.2 days for riluzole; 9.8 days for PBO). However, the study was not adequately powered to show a difference between the two treatment groups. In another RCT, riluzole was administered at a daily dose of 100-200 mg following a ketamine infusion (0.5 mg/kg). 26 There was no significant difference in time-to-relapse with riluzole, when compared to PBO (24.4 days and 22.0 days, respectively). A combination of single iv dose of ketamine (0.5 mg/kg) and escitalopram (10 mg daily) was studied in patients with severe MDD. 27 Compared to escitalopram therapy alone, the combination group had a significantly higher response rate (92.3% vs 57.1%), remission rate (76.9% vs 14.3%), shorter time to response (HR=0.04 95% CI=0.01-0.22), and remission (HR=0.11, 95% CI=0.02-0.63).
Oral ketamine
Oral ketamine has been investigated as an antidepressant treatment in patients with mild-to-moderate depression and concomitant chronic pain (Table 5) . 28 When compared to diclofenac, ketamine, dosed at 50 mg orally three times a day, showed significant improvement in HDRS (mean difference=2.85, 95% CI 0.54-5.16) and Hospital Anxiety and Depression Scale (HADS) scores (mean difference=0.75, 95% CI 0.18-1.32) at week 6 of treatment.
Intranasal ketamine
A recently conducted study compared three different doses of S-(+)-ketamine enantiomer (esketamine) (28 mg, 54 mg, and 84 mg) administered intranasally vs PBO, and found that all three doses significantly decreased MADRS in both phases of the studies. 29 However, in patients with severe MDD and at imminent risk of suicide, intranasal esketamine (84 mg), along with standard of care, was shown to be superior to PBO in reducing symptoms of depression. 30 These two studies are summarized in Table 6 .
Adverse effects of ketamine
In contrast to most anesthetic agents that are typically hypotensive, ketamine increases heart rate and blood pressure via centrally mediated adrenergic response; and, while this may be useful in trauma or shock situations, the parasympathetic and sympathetic responses to ECT result in transient hypotension and bradycardia followed by hypertension and tachycardia. Ketamine anesthesia is, thus, associated with temporary increases in pulse rate and blood pressure (BP), with a median systolic and diastolic peak increase of 20%-25% from baseline. (2) Studies have reported a significant QTc interval prolongation (up to 20.7 ms) and an increase in mean arterial BP (range of 9.8-22.5 mmHg). 8, 10, 12, 13, 19, 21 This may be clinically significant, considering that many psychotropics (antidepressants, antipsychotics, lithium) prolong QTc interval. 
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Ketamine's role in eCT and non-eCT settings Table 3 iv Ketamine in a non-eCT setting RCT: Groups A and C received 1.0 mg/kg of iv ketamine, 1.5 mg/kg iv propofol, and 2 mcg/kg iv fentanyl. Group B received 1.5 mg/kg iv propofol and 2 mcg/kg iv fentanyl. 
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Ketamine's role in eCT and non-eCT settings While ketamine preserves airway reflexes and spontaneous respirations versus other agents such as methohexital or propofol, because muscle relaxants (paralytics) must be used in ECT, ventilation still needs to be supported. Hypersalivation may be a problem, especially in patients without a secured airway. Increased muscle tone can occur and may manifest as tonic-clonic movements. Ketamine induces theta activity and suppresses alpha activity; an EEG study of 14 patients did not show any seizure activity, but epileptiform attacks have been reported. 2 Increased confusion, restlessness, headaches, fear, and derealization have also been observed as adverse effects of ketamine use in anesthesia. 7, 13, 14, 19 Hallucinations or delusions were rarely observed. 7, 11, 19 The S-ketamine enantiomer (esketamine) has a threefold to fourfold greater affinity for NMDA receptors than the R-ketamine enantiomer (arketamine), and has been associated with post-treatment disorientation and restlessness. 7 It has been reported that arketamine, compared to esketamine or racemic ketamine, may have a lower rate of adverse effects related to NMDA inhibition such as dissociation, dizziness, sensory, and perceptual deficits. 31 Additionally, rates of both cardiovascular and psychotomimetic effects appear to be lower if ketamine is used in combination with propofol, when compared to ketamine as a sole agent. 8, 9 The US Food and Drug Administration (FDA) has very recently issued new warnings about the safety of general anesthetic and sedative (benzodiazepine) drugs, based on animal studies showing prolonged exposure causes widespread loss of nerve cells in the developing brain. 
Clinical predictors of response to ketamine
One study has demonstrated ketamine's antidepressant effects to be more pronounced in individuals with TRD who had a family history of alcohol dependence in a first-degree relative. 33 Other clinical predictors of response to ketamine are summarized in Table 7 . [34] [35] [36] A pooled analysis of National Institute of Mental Health (NIMH) data reported that this factor accounted for 22% variance in percent change of HDRS scores, and was the strongest single clinical predictor of response to ketamine. 33 This observation was further supported by a study conducted by Niciu et al, 34 where a single dose of iv ketamine (0.5 mg/kg) was administered followed by a flexible dose of riluzole (100-200 mg daily) or PBO for 4 weeks. Family history-positive patients had an extended delay in time-to-relapse by an average of 13.4 days. However, personal history of alcohol dependence did not predict 
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Ketamine's role in eCT and non-eCT settings 35 showed that ketamine demonstrated greater efficacy in anxious TRD than in non-anxious TRD; the former group also remained in remission for longer. Finally, in terms of cognitive factors, patients with slower processing speed at baseline may have a better response to ketamine at 24 h post-infusion, as demonstrated by Murrough et al. 36 
Discussion
In an ECT setting, ketamine may accelerate initial response when used alone or in combination with non-barbiturate agents such as propofol, and at doses of equal to or higher than 0.8 mg/kg. Stronger conclusions around dose-related efficacy in the ECT setting would require further research with more rigorous trials, as well as a meta-analysis to account for the significant heterogeneity of the studies included. While most studies using doses equal to or higher than 0.8 mg/kg did demonstrate a significant reduction in depressive symptoms, this finding was not consistent among all studies, and limited our ability to draw a conclusion around this specific objective (Table 2) . Propofol does appear to mitigate some of ketamine's adverse effects, including cardiotoxicity, psychotomimetic effects, vomiting, and recovery agitation, without reducing efficacy. 8, 9 Ketamine, in turn, mitigates propofol-induced hypotension. 9 When combined with barbiturates such as thiopental, ketamine has not been shown to be effective in reducing depressive symptoms, likely due to the effects of barbiturates in attenuating seizures as a result of their anticonvulsant properties. 7, 11, 15, 16 Ketamine may have a role as an adjunctive agent to a non-barbiturate anesthetic, or as a sole anesthetic to accelerate response in the severely ill and those at risk of suicide. While iv ketamine remains the main route of administration, a few studies have demonstrated promising results in non-ECT settings when using alternate routes, notably intranasal. 29, 30 Safety concerns in the setting of ECT include higher rates of hypertension, QTc interval prolongation, transient arrhythmias, confusion, or fear, with hallucinations upon awakening from anesthesia. [7] [8] [9] 12, 16, 23, 25 The rates of these effects appear to have a positive correlation with an increasing dose of ketamine, notably in the 0.8-2.0 mg/kg dosing range. 8, 9, 12, 16, 23, 25 Ketamine use in patients with cardiovascular disease should be considered with caution, especially when used in an ECT setting. Ketamine should also be considered with caution in patients with a history of psychotic episodes, due to its potential psychotomimetic effects. Concomitant use of propofol may be considered to mitigate some of these adverse effects. 8 However, this does add to complexity and cost. It is important to note that most of these adverse effects are transient in nature, and subside shortly after completion of an ECT session. 7, 15, 18 Therefore, an individual risk-benefit analysis should be considered.
One of the biggest challenges in using ketamine for treatment of MDD appears to be the maintenance of response to ketamine. 23, 25, 26 There are concerns regarding the use of ketamine as a maintenance treatment, including: (1) lack of evidence supporting such use; (2) lack of long-term safety data; and (3) logistical difficulties associated with administration in an outpatient setting. Riluzole has thus far not shown a statistically significant difference over PBO in maintenance of the response induced by ketamine. 25, 26 Although riluzole shows theoretical promise, larger and more rigorous RCTs will have to be carried out to investigate the hypothesis. Hu et al 27 demonstrated that a combination of ketamine with escitalopram was more efficacious in achieving and sustaining response and remission than escitalopram alone. This observation suggests that patients should be maintained on existing oral antidepressant therapy during and after receiving ketamine treatment. Lenze et al 23 found that prolonged ketamine infusion (96 h) may offer a more sustained antidepressant response. Safety concerns regarding such a prolonged infusion may be greater than with the standard total of six 40-min infusions, particularly given recent animal data demonstrating neurotoxicity with chronic sub-anesthetic iv doses of ketamine. 37 A study by Daly et al 29 demonstrated that administration of intranasal esketamine for up to 74 days may be an option to maintain response and remission. Self-administration of esketamine presents another concern in terms of risk for abuse. Ketamine remains a restricted drug in most jurisdictions. Tolerance, dependence, and withdrawal have been reported with long-term use. 2 The studies investigating the clinical predictors of ketamine's efficacy in TRD are indeed interesting. 33 The evidence to date suggests that ketamine may potentially be more beneficial for patients with a history of a first-degree relative with alcohol dependence, patients suffering from anxious depression, patients with slower processing speed at baseline, patients suffering from depression and undergoing a surgery, and patients who are around 50 years of age. 26, [34] [35] [36] It is important to note that, currently, such evidence may only be interpreted as signals, and further research is needed to better understand the clinical predictors of ketamine's efficacy in TRD.
Limitations
There are a few limitations to this literature review. A full meta-analysis was not performed, and only published English language studies were included. The average level of evidence was 3; many studies were at high risk for bias, given the lack of blinding, and the majority had less than 50 participants. Small samples are underpowered to conclude a meaningful difference between treatment groups. Additionally, the populations included in these studies were heterogeneous and included patients with differing durations of illness and on different antidepressant treatments. Ketamine has been principally investigated in patients with chronic and severe depression who may have altered neurobiology and pharmacological responses, when compared to patients who are relatively early into their illness. 38, 39 Therefore, the results cannot be generalized to all patients suffering from MDD, and it is important to recognize that even small changes in depressive symptoms may be more meaningful or accepted in a population of patients with very treatmentresistant depression. Studies also differed in ECT administration techniques and depression rating scales used. There are only limited data regarding validity of depression rating scales used more frequently than weekly, whereas changes in ketamine response may occur on an hourly to daily basis. 26 Some studies have also used PBO controls, but ketamine's psychotomimetic effects render full blinding difficult. 23, 24, 29, 30 The majority of the studies allowed concomitant medications, which increases inter-patient variability, and exacerbates potential risk for specific interactions with ketamine. Finally, only short-term effects of ketamine have been explored, thus leaving the question of long-term safety unanswered. This is particularly relevant given the recent class warning for anesthetic and sedative agents.
Conclusion
Ketamine warrants consideration as an agent for use in an ECT setting and may accelerate response. However, the evidence is mixed, the effect is modest at best, and many questions regarding optimal dosing strategies remain unanswered. The long-term safety of ketamine is still unknown, and there are recent class concerns with respect to the use of most anesthetic agents. Ketamine may be more efficacious in patients with certain clinical predictors, but requires further investigation to confirm the same. It should be used with caution or avoided in certain patients with additional risk factors for cardiovascular or psychotomimetic adverse effects.
Additional rigorous, well-controlled, randomized, double-blinded studies are needed that would further explore different dosing strategies and routes of administration for ketamine in ECT and non-ECT settings, in order to address risks and benefits.
